Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram

American Journal of Geriatric Psychiatry

Volumn 25, Issue 5, 2017, Pages 512-519

  Robinson, Robert G ^a   Jorge, Ricardo E ^c   Long, Jeffrey ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

antidepressants; Mortality; post stroke depression; stroke

Indexed keywords

ESCITALOPRAM; PLACEBO; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY ASSESSMENT; DOUBLE BLIND PROCEDURE; EXPERIMENTAL DESIGN; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MORTALITY; NEUROLOGIC EXAMINATION; POST-STROKE DEPRESSION; PROBLEM SOLVING THERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; AGED; COMPLICATION; DEPRESSION; PROBLEM SOLVING; TIME FACTOR;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROBLEM SOLVING; PSYCHOTHERAPY; STROKE; TIME FACTORS;

EID: 85006014402     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2016.10.001     Document Type: Article

References (28)

1. 1 Morris, P.L., Robinson, R.G., Andrzejewski, P., et al. Association of depression with 10-year poststroke mortality. Am J Psychiatry 150 (1993), 124–129.
2. 2 Morris, P.L., Robinson, R.G., Samuels, J., Depression, introversion and mortality following stroke. Aust N Z J Psychiatry 27 (1993), 443–449.
3. 3 House, A., Knapp, P., Bamford, J., et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 32 (2001), 696–701.
4. 4 Ayerbe, L., Ayis, S., Crichton, S.L., et al. Explanatory factors for the increased mortality of stroke patients with depression. Neurology 83 (2014), 2007–2012.
5. 5 Ayerbe, L., Ayis, S., Wolfe, C.D., et al. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry 202 (2013), 14–21.
6. 6 Jorge, R.E., Robinson, R.G., Arndt, S., et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 160 (2003), 1823–1829.
7. 7 Robinson, R.G., Jorge, R.E., Moser, D.J., et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 299 (2008), 2391–2400.
8. 8 Mikami, K., Jorge, R.E., Moser, D.J., et al. Increased frequency of first-episode poststroke depression after discontinuation of escitalopram. Stroke 42 (2011), 3281–3283.
9. 9 Baldessarini, R.J., Tondo, L., Ghiani, C., et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 167 (2010), 934–941.
10. 10 Narushima, K., Kosier, J.T., Robinson, R.G., Preventing poststrok e depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 190 (2002), 296–303.
11. 11 Adams, H.P. Jr, Bendixen, B.H., Kappelle, L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993), 35–41.
12. 12 De Renzi, E., Vignolo, L.A., The Token Test: a sensitive test to detect receptive disturbances in aphasics. Brain 85 (1962), 665–678.
13. 13 First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B., Structured Clinical Interview for DSM-IV (SCID). New York, NY, Biometric Research, 1995.
14. 14 Hamilton, M., A rating scale for depression. J Neurol Neurosurg Psychiatry, 23, 1960, 56.
15. 15 Forer, S., Functional Independence Measure. 1987, State University of New York at Buffalo, Buffalo, NY.
16. 16 Robinson, R.G., Bolduc, P.L., Kubos, K.L., et al. Social functioning assessment in stroke patients. Arch Phys Med Rehabil 66 (1985), 496–500.
17. 17 Linn, B.S., Linn, M.W., Gurel, L., Cumulative illness rating scale. J Am Geriatr Soc 16 (1968), 622–626.
18. 18 Hegel, M.T., Barrett, J.E., Cornell, J.E., et al. Predictors of response to problem-solving treatment of depression in primary care. Behav Ther 33 (2002), 511–527.
19. 19 Kalbfleisch, J.D., Prentice, R.L., The Statistical Analysis of Failure Time Data. 2002, Wiley-Interscience.
20. 20 Therneau, T.M., Grambsch, P.M., Modeling Survival Data: Extending the Cox Model. 2000, Springer Science & Business Media.
21. 21 Bartoli, F., Lillia, N., Lax, A., et al. Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat, 2013, 2013 862978.
22. 22 Ried, L.D., Jia, H., Feng, H., et al. Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality. Ann Pharmacother 45 (2011), 888–897.
23. 23 Kusumi, I., Koyama, T., Yamashita, I., Serotonin-stimulated Ca2+ response is increased in the blood platelets of depressed patients. Biol Psychiatry 30 (1991), 310–312.
24. 24 Smoller, J.W., Allison, M., Cochrane, B.B., et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 169 (2009), 2128–2139.
25. 25 Hackam, D.G., Mrkobrada, M., Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 79 (2012), 1862–1865.
26. 26 Jorge, R.E., Acion, L., Moser, D., et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 67 (2010), 187–196.
27. 27 Santarelli, L., Saxe, M., Gross, C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003), 805–809.
28. 28 Banasr, M., Hery, M., Printemps, R., et al. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 29 (2004), 450–460.